Similarly, combined dabrafenib and trametinib resulted in growth-inhibitory synergism in 5/6 pancreatic cancer cell lines (all carrying a KRAS mutation, with the exception of T3 M4 and the non-neoplastic cell line HPDE) and frank antagonism in the KRAS-mut PANC1 cell line (Additional file 1: Table S1 and Additional file 1: Figure S4). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.